Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the ...

Market opportunities lie in modernizing software development and validation approaches, emphasizing agility and continuous validation to meet changing needs, while ensuring compliance with FDA ...

New Wave Biotech has launched a new Life Cycle Assessment (LCA) tool tailored to the biotechnology sector, designed to ...

The companies will use clinical trial plasma samples and data to drive the AthosOmics.AI platform to identify efficacy biomarkers for Xeptiva's lead experimental therapeutic vaccine for canine ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using AI to discover new drugs. | Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers ...

When it comes to avoiding scams, most of us would rather be safe than sorry. You might not be able to prove that an ...

Baron International Growth Fund gained 6.04% during the quarter, slightly underperforming its benchmark, the MSCI ACWI ex USA ...

Private equity-backed Clario brings to Thermo Fisher Scientific software that collects, manages, and analyzes clinical trial ...

To view the full press release, visit https://ibn.fm/HAV6r ...